Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 10;14(1):e075948.
doi: 10.1136/bmjopen-2023-075948.

Serotype 3 Experimental Human Pneumococcal Challenge (EHPC) study protocol: dose ranging and reproducibility in a healthy volunteer population (challenge 3)

Phoebe Hazenberg  1 , Ryan E Robinson  1   2 , Madlen Farrar  1 , Carla Solorzano  1   3 , Angela Hyder-Wright  1   2 , Konstantinos Liatsikos  1 , Jaye Brunning  1 , Hannah Fleet  1 , Amy Bettam  1 , Ashleigh Howard  1 , Tinashe Kenny-Nyazika  1 , Britta Urban  1   3 , Elena Mitsi  1   3 , Dima El Safadi  1 , Kelly Davies  1 , Maia Lesosky  4 , Stephen B Gordon  1   5 , Daniela M Ferreira  1   3 , Andrea M Collins  6   2
Affiliations

Serotype 3 Experimental Human Pneumococcal Challenge (EHPC) study protocol: dose ranging and reproducibility in a healthy volunteer population (challenge 3)

Phoebe Hazenberg et al. BMJ Open. .

Abstract

Introduction: Since the introduction of pneumococcal conjugate vaccines, pneumococcal disease rates have declined for many vaccine-type serotypes. However, serotype 3 (SPN3) continues to cause significant disease and is identified in colonisation epidemiological studies as one of the top circulating serotypes in adults in the UK. Consequently, new vaccines that provide greater protection against SPN3 colonisation/carriage are urgently needed. The Experimental Human Pneumococcal Challenge (EHPC) model is a unique method of determining pneumococcal colonisation rates, understanding acquired immunity, and testing vaccines in a cost-effective manner. To enhance the development of effective pneumococcal vaccines against SPN3, we aim to develop a new relevant and safe SPN3 EHPC model with high attack rates which could be used to test vaccines using small sample size.

Methods and analysis: This is a human challenge study to establish a new SPN3 EHPC model, consisting of two parts. In the dose-ranging/safety study, cohorts of 10 healthy participants will be challenged with escalating doses of SPN3. If first challenge does not lead into colonisation, participants will receive a second challenge 2 weeks after. Experimental nasopharyngeal (NP) colonisation will be determined using nasal wash sampling. Using the dose that results in ≥50% of participants being colonised, with a high safety profile, we will complete the cohort with another 33 participants to check for reproducibility of the colonisation rate. The primary outcome of this study is to determine the optimal SPN3 dose and inoculation regime to establish the highest rates of NP colonisation in healthy adults. Secondary outcomes include determining density and duration of experimental SPN3 NP colonisation and characterising mucosal and systemic immune responses to SPN3 challenge.

Ethics and dissemination: This study is approved by the NHS Research and Ethics Committee (reference 22/NW/0051). Findings will be published in peer-reviewed journals and reports will be made available to participants.

Keywords: Adult thoracic medicine; BACTERIOLOGY; Clinical Trial; Immunology; Respiratory infections.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Trial flow chart. *Isolate 2 may not be tested at the discretion of the trial steering committee. CFU, colony-forming unit; CI, chief investigator.
Figure 2
Figure 2
(A) Dose-ranging study sampling schedule. (B) Reproducibility study sampling schedule. CPS, capsular polysaccharide; IgG, immunoglobulin G; SPN3, Streptococcus pneumoniae serotype 3. Created with Biorender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. GLRI C. Estimates of the global, regional, and national morbidity, mortality, and Aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis 2018;18:1191–210. - PMC - PubMed
    1. German EL, Solórzano C, Sunny S, et al. . Protective effect of PCV vaccine against experimental Pneumococcal challenge in adults is primarily mediated by controlling Colonisation density. Vaccine 2019;37:3953–6. 10.1016/j.vaccine.2019.05.080 - DOI - PMC - PubMed
    1. Levine OS, O’Brien KL, Knoll M, et al. . Pneumococcal vaccination in developing countries. Lancet 2006;367:1880–2. 10.1016/S0140-6736(06)68703-5 - DOI - PubMed
    1. Oligbu G, Collins S, Djennad A, et al. . Effect of Pneumococcal conjugate vaccines on Pneumococcal meningitis. Emerg Infect Dis 2019:1708–18. 10.3201/eid2509.180747 - DOI - PMC - PubMed
    1. de Miguel S, Domenech M, González-Camacho F, et al. . Nationwide trends of invasive Pneumococcal disease in Spain from 2009 through 2019 in children and adults during the Pneumococcal conjugate vaccine era. Clin Infect Dis 2021;73:e3778–87. 10.1093/cid/ciaa1483 - DOI - PubMed

Publication types

Substances

LinkOut - more resources